Abstract 1857P
Background
The COVID-19 pandemic has been closely associated with a decline in mental health. The goal of this study was to identify the degree of distress of cancer patients before and after the pandemic and to find out if COVID-19 worsened the mental health of cancer patients.
Methods
A self-rated survey was conducted for 2 groups of patients at The Todua Clinic, Tbilisi, Georgia twice: at the peak of pandemic and again 6 months after the pandemic. Study included adult cancer patients, with solid tumors, over 18 years of age, receiving chemotherapy, being able to understand and answer the questions in written English. Event Scale-Revised (IES-R) test was implemented to measure Post-Traumatic Stress Disorder (PTSD). Total IES-R score of 33 or over signifies the likely presence of PTSD.
Results
Study enrolled total of 195 patients, 103 patients - during and 92 - after the pandemic. 3 independent and 5 dependent variables were created. Independent variables were: 1. IES-R score ≥24 ( y=1 if score ≥ 24, y=0 if score ≤ 24); 2. IES-R score≥ 33 (y=1 if score ≥ 33, y=0 if score ≤ 33); 3. IES-R score 37 (y= 1 if score ≤ 37, y=0 f score ≤ 37). Five dependent variables were: time, type of disease, stage, sex, and marital status. We created 3 regression models with independent and dependent variables (model 1: independent variable was IES-R score ≥24, model 2 independent variable was - IES-R score ≥ 33, model 3 IES-R score ≥ 33). We observed improvement in IES-R scores in the post-pandemic period: In model 1 - results improved by 20%, In model 2 - 16%, and in model 3 – 14%. Female and married individuals had better results in both periods. We calculated the data and observed that all dependent variables other than the disease type and the disease stage had a significant impact on IES-R scores.
Conclusions
Our findings showed a significant difference in IES-R scores in patients before and after the COVID-19 pandemic, with notable improvement in the post-COVID period. We also observed that sex, disease stage, marital status, and disease stage affected IES-R scores. We conclude that COVID-19 worsened the mental health of cancer patients. Our study highlighted the need for efforts to better integrate psychosocial support into cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05